Rituximab therapy in pediatric pemphigus patients: A retrospective analysis of five Turkish patients and review of the literature

Basit Öğe Kaydı
dc.contributor.authorBilgic-Temel, Asli
dc.contributor.authorOzgen, Zueleyha
dc.contributor.authorHarman, Mehmet
dc.contributor.authorKapicioglu, Yelda
dc.contributor.authorUzun, Soner
dc.date.accessioned2024-04-24T17:11:49Z
dc.date.available2024-04-24T17:11:49Z
dc.date.issued2019
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground/Objectives There is inadequate knowledge regarding rituximab (RTX) administration in autoimmune bullous diseases (AIBDs), disease prevalence, clinical characteristics, and treatment outcomes within pediatric populations due to the rarity of AIBDs affecting the pediatric age group. The aim of this retrospective analysis was to evaluate the effectiveness, safety of RTX, and treatment outcomes in Turkish pediatric patients with pemphigus vulgaris (PV) and to review the literature. Methods Five patients under 18 years of age and diagnosed with PV received RTX treatment and were identified in four dermatology departments of Turkey. Results The mean age of the patients at the time of RTX therapy initiation was 15 years (range: 11-17 years), and the total duration of follow-up after RTX therapy was 42.6 months (range: 19-60 months). All patients showed a clinical response. At the last visit, complete remission off therapy was achieved in three patients. The remaining two patients achieved partial remission off therapy. No adverse events were observed. Conclusions This retrospective case series of five pediatric patients showed that RTX treatment can be effective and safe for the treatment of recalcitrant PV in pediatric patients. With increasing evidence, RTX is a good treatment choice in adults and pediatric patients with pemphigus.en_US
dc.identifier.doi10.1111/pde.13926
dc.identifier.endpage650en_US
dc.identifier.issn0736-8046
dc.identifier.issn1525-1470
dc.identifier.issue5en_US
dc.identifier.pmid31355479
dc.identifier.scopus2-s2.0-85072280408
dc.identifier.scopusqualityQ2
dc.identifier.startpage646en_US
dc.identifier.urihttps://doi.org/10.1111/pde.13926
dc.identifier.urihttps://hdl.handle.net/11468/17732
dc.identifier.volume36en_US
dc.identifier.wosWOS:000478449100001
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofPediatric Dermatology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectChildhood Pemphigusen_US
dc.subjectJuvenile Pemphigusen_US
dc.subjectPediatric Pemphigusen_US
dc.subjectRituximaben_US
dc.subjectTherapyen_US
dc.titleRituximab therapy in pediatric pemphigus patients: A retrospective analysis of five Turkish patients and review of the literatureen_US
dc.titleRituximab therapy in pediatric pemphigus patients: A retrospective analysis of five Turkish patients and review of the literature
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu